(Q37449058)

20 August 2017

1 reference

title

Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab (English)

1 reference

20 August 2017

1 reference

1 reference

hepatocellular carcinoma

1 reference

Richard S Finn

1

1 reference

20 August 2017

Andrew X Zhu

series ordinal

2

1 reference

20 August 2017

publication date

1 April 2009

1 reference

Expert Review of Anticancer Therapy

20 August 2017

published in

1 reference

20 August 2017

volume

9

1 reference

20 August 2017

issue

4

1 reference

20 August 2017

page(s)

503-509

1 reference

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

20 August 2017

cites work

1 reference

Focus on hepatocellular carcinoma.

21 January 2018

1 reference

Non-alcoholic steatohepatitis and cancer

21 January 2018

1 reference

21 January 2018

Cancer statistics, 2008

1 reference

Management of hepatocellular carcinoma

21 January 2018

1 reference

A critical appraisal of the literature on local ablative therapies for hepatocellular carcinoma.

21 January 2018

1 reference

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

21 January 2018

1 reference

Hepatocellular carcinoma: the need for progress.

21 January 2018

1 reference

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

Opportunities for targeted therapies in hepatocellular carcinoma

21 January 2018

1 reference

Transarterial chemoembolization for patients with hepatocellular carcinoma.

21 January 2018

1 reference

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

21 January 2018

The Hallmarks of Cancer

1 reference

Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma?

21 January 2018

1 reference

Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery

21 January 2018

1 reference

High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies

21 January 2018

1 reference

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma

21 January 2018

1 reference

Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.

21 January 2018

1 reference

Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma

21 January 2018

1 reference

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

21 January 2018

1 reference

Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model

21 January 2018

1 reference

Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma

21 January 2018

1 reference

siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo

21 January 2018

1 reference

Regression of established tumors and metastases by potent vascular endothelial growth factor blockade

21 January 2018

1 reference

Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.

21 January 2018

1 reference

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

21 January 2018

1 reference

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study

21 January 2018

1 reference

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

21 January 2018

1 reference

Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.09.6

1 reference

20 August 2017

1 reference